A Pilot Study of IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

What's the purpose of this trial?

This study proposes a safe dosing regimen IFN-γ that is sufficient to stimulate IFN-γ receptors on malignant blasts in patients who developed relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after alloSCT with no active or history of III-IV acute graft-versus-host disease (GVHD). It is hypothesized that IFN-γ will promote graft-vs-leukemia (GVL) in patients with AML/MDS that has relapsed after alloSCT.

This trial is currently open and accepting patients.

What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

* Recipients of allogeneic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome from a human leukocyte antigen (HLA) matched donor
* Relapsed of primary disease with 5% to 20% of blasts in the bone marrow by flow cytometry in the bone marrow with an clear leukemia-associated immunophenotype (If the patient received therapy to treat the relapse, he or she must have 5-20% residual blasts prior to enrollment on this study)
* Performance status KPS score \>60% (ECOG 0-2)
* No increases in systemic immunosuppression in the prior four weeks other than to maintain therapeutic levels
* No systemic corticosteroid with a dose higher than 0.5mg/kg/day prednisone or equivalent
* No history of grade IV acute GVHD
* No new systemic immunosuppressive medications in the prior two weeks initiated due to GVHD
* Willingness to have bone marrow and peripheral blood collected as per the study protocol
* Must be able to give informed consent
* Age 18 or older

Exclusion Criteria:

* Contraindication to receive IFN-γ including known hypersensitivity to interferon-gamma, E. coli derived products or any component of the product
* Subjects with a positive pregnancy test or who are breastfeeding
* For men or women of childing bearing potential (age \< 50 without hysterectomy or oophorectomy or documented menopause), unwilling to use effective contraception for the duration of the study.
* Primary engraftment failure
* Active cardiac arrhythmias not controlled by medical management or current NYHA class II or higher congestive heart failure
* Active ischemic heart disease not well controlled with medications
* A seizure disorder not well controlled by medications
* Estimated GFR \<30 mL/min
* AST/SGOT or ALT/SPOT \> 5 x ULN
* Total bilirubin \> 3 x ULN
* Chemotherapy (other than hypomethylating and/or venetoclax therapy) within the prior 4 weeks
* Body surface area at or less than 1.5 m2, or greater than 2.5 m2 so as to minimize the variation in IFN-γ exposure based on differences in BSA.
* Patients less than 18 years old.
* Pregnant or breastfeeding patients.

Additional Trial Information

Phase 1

Enrollment: 6 patients (estimated)

View More
Need Help?

Interested in joining or learning more about this trial?

(888) 828-2206

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Pennsylvania

UPMC Hillman Cancer Center University of Pittsburgh Medical Center (UPMC)

Pittsburgh, PA

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • Add this trial to your favorites keyboard_arrow_right

    If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message